NCDs, Part II: Evidence Development to Fulfill CED Requirements
Avalere Essential Voice
English - June 22, 2022 18:07 - 20 minutes - 28.8 MBMedicine Health & Fitness Science Life Sciences Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.